Leslie Raffini, MD, MSCE is an Associate Professor of Pediatrics at the Children’s Hospital of Pediatrics (CHOP), Perelman School of Medicine, University of Pennsylvania. She is a pediatric hematologist and is medical director of the Hemostasis and Thrombosis Center (HTC) at CHOP.
She completed her residency in pediatrics at Johns Hopkins Hospital, followed by a fellowship in pediatric hematology and oncology at CHOP. She obtained her Masters in Clinical Epidemiology from UPENN.
Dr. Raffini’s academic career has focused on clinical investigation of bleeding and clotting disorders in children for nearly 20 years. Locally, she is the director of the Anticoagulation Safety Program and co-director of the Cardiac Anticoagulation and Thrombosis Service. She has served on several national/international panels and committees as an expert in pediatric venous thromboembolism, including the American Society of Hematology Venous Thrombosis Guideline Panel and the Co-chair of the International Society on Thrombosis and Haemostasis (ISTH) Pediatric Scientific and Standardization Committee (SSC). She has participated in numerous industry sponsored trials of drugs and devices in in pediatric thrombosis, including membership on the Critical Events Committee for the EXCOR Pediatric Ventricular Assist Device International Trial; the Data Safety Monitoring Board for a dose-finding study of fondaparinux in children (GlaxoSmithKline); and monitoring board of a study of desulfated heparin in children (ParinGenix). She has been principal investigator on investigator-initiated clinical trials of argatroban and bivalirudin in children, and on industry sponsored pediatric trials of rivaroxaban (Bayer), apixaban (Pfizer), and edoxaban (Daiici Sankyo) for the treatment of venous thromboembolism in children.
Dr Raffini’s main research interests include prevention of thrombosis in children, particularly those with congenital heart disease, and optimization of therapy for treatment of pediatric thrombosis. She is Chair of the ISTH Pediatric SSC working group that is focused on Risk Stratification and Thromboprophylaxis for children. She is also leading national (sponsored by the American Thrombosis and Hemostasis Network) and international registries (International Pediatric Thrombosis Network) focused on collecting real-world data on children treated with direct oral anticoagulants.